NCT01460875 - Recombinant Interferon Alfa-2b in Treating Patients With Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 22, 2008

Primary Completion Date

January 5, 2014

Study Completion Date

January 5, 2014

Conditions

Stage IA Skin MelanomaStage IB Skin MelanomaStage IIA Skin MelanomaStage IIB Skin MelanomaStage IIC Skin MelanomaStage IIIA Skin MelanomaStage IIIB Skin MelanomaStage IIIC Skin MelanomaStage IV Skin Melanoma

Interventions

BIOLOGICAL

recombinant interferon alfa-2b

Given SC

OTHER

laboratory biomarker analysis

Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.

Trial Locations (1)

43210

Ohio State University Medical Center, Columbus